Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Initial development in PIDs with immune dysregulation linked to PI3K? signaling

Continue reading here:
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Related Posts